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Abstract
Objective. Decoy receptor 3 (DcR3), a member of the tumor necrosis factor receptor superfamily, is ampliﬁed and over-
expressed in various cancers. The objective of the present study was to investigate the concentration of DcR3 in sera of
hepatocellular carcinoma (HCC) patients and its clinical signiﬁcance.
Methods. Serum concentrations of DcR3 were measured by enzyme-linked immunosorbent assay (ELISA) in 67 patients with
HCC, 8 with liver cirrhosis, 17 with cholecystitis, and in 28 healthy individuals. Immunohistochemistry was employed to
access protein expression of DcR3 in the corresponding HCC tissues.
Results. Serum concentrations of DcR3 in patients with HCC or cirrhosis were signiﬁcantly higher than in healthy individuals
(P < 0.01). Moreover, serum concentrations of DcR3 in HCC patients were associated with TNM stage, para-cirrhosis,
capsular inﬁltration, and metastasis or recurrence of disease (P < 0.05). There was a positive correlation between the serum
concentration of DcR3 and protein expression in HCC tissues (r = 0.472, P < 0.01).
Conclusions. The high serum concentration of DcR3 might play a certain role in pathogenesis, progress, and metastasis of HCC.
Moreover, DcR3 might serve as a valuable molecular indicator in early diagnosis and contribute to predicting the clinical
outcome in HCC patients.
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Introduction
Hepatocellular carcinoma (HCC) is the ﬁfth most
common cause of cancer deaths in the world with
an increasing incidence (1–3). Although the prognosis
of HCC patients has marginally been improved over
the last two decades, the 5-year survival rate still
remains around 5% (4,5). Presently, standard sur-
veillance includes a combination of 6-monthly
abdominal ultrasound scans and serum alphafetopro-
tein (AFP) measurements, but this strategy cannot
reliably detect early liver tumors. Serum AFP may
also be elevated in cirrhosis, especially with viral
hepatitis, in the absence of HCC. The differential
diagnosis of elevated serum AFP concentrations also
includes gastric, biliary, and pancreatic cancers and
germ cell tumors (6). The relatively suboptimal sen-
sitivity of conventional serum AFP as a marker has led
to a search for more sensitive and speciﬁc markers (7).
It has been reported that decoy receptor 3 (DcR3)/
TR6/M68 was over-expressed in various malignant
tumor tissues as regards both mRNA and protein
levels (8–17). In addition, serum concentrations of
DcR3 were elevated in cancers of the stomach, liver,
pancreas, gall-bladder, colon, thyroid, lung, kidney,
breast, and ovary (8–12) as well as in gliomas (17).
Our group previously studied the protein expression
of DcR3 in HCC microarrays and found that the
positive rate of DcR3 in HCC tissues was signiﬁcantly
higher than that in para-cancerous, cirrhosis, and
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with clinical TNM stages, the status of metastasis or
recurrence of disease, serum AFP concentration,
portal vein tumor emboli, capsular inﬁltration, and
multiple tumor nodes (14). Compared to the evalu-
ation of DcR3 protein detection, Wu et al. (8) estab-
lished an enzyme-linked immunosorbent assay
(ELISA) to measure DcR3 serum concentrations in
HCC, and 74.3% (26/35) of the patients were found
to be DcR3-positive (>20 pg/mL). Likewise, liver
cirrhosis was found to be a condition with elevated
serum DcR3 concentrations. Immunohistochemistry
was performed to examine the DcR3 expression in
HCC and cirrhosis tissues by Wu et al. (8). However,
only a small number of samples were examined. To
our knowledge, no studies have evaluated the associa-
tions between DcR3 serum concentrations and pro-
tein expression and clinical parameters in the same
HCC patient population. Therefore, we investigated
the relationship between DcR3 serum concentrations
and its protein expression in HCC tumor tissues and
clinicopathological parameters.
Patients and methods
Patients
Serum samples were collected at the First Afﬁliated
Hospital, Guangxi Medical University, China, bet-
ween September 2006 and September 2007 from
patients with HCC (n = 67), cirrhosis (n = 8), or
cholecystitis (n = 17) and also from healthy controls
(n = 28). Clinical information was obtained from
medical records. The age of the HCC patients ranged
from 29 to 74 years, with a mean of 48 years. Among
the 67 patients, 58 were male and 9 female. HBV
infection status was based on hepatitis B surface
antigen (HBsAg). Fifty-one patients were HBsAg-
positive, and ten were found to be anti-HCV-positive.
There were six anti-HCV-positive cases that were co-
infected with HBV, and six cases were both HBsAg-
negative and anti-HCV-negative. The histopathologic
diagnoses were made according to the World Health
Organization international histological classiﬁcation
of HCC: well differentiated (n = 16), moderately
differentiated (n = 37), or poorly differentiated
(n = 14). According to the clinical tumor–node–
metastasis (TNM) standard, their clinical stages
were stage I (n = 26), stage II (n = 11), stage III
(n = 19), and stage IV (n = 11). All 67 HCC patients
were followed up for 20 months by measurements of
tumor markers (AFP) and ultrasound (US), as well as
helical computed tomographic (CT) scan. Forty cases
had metastasis or recurrence of disease, 27 cases did
not. Forty-four cases had para-cirrhosis. Sixty-four
samples of HCC tissues were collected from hepatec-
tomies. All 64 cases were initial hepatectomies in
order to avoid the secondary changes of healing post
biopsy. All the 67 HCC patients had never received
any radiation therapy or chemotherapy. Diagnosis
and classiﬁcation were based on histology or cytology
by the same pathologist. Among eight cirrhotic sam-
ples, six were male, two female. The range of age was
between 28 and 60 years, with a mean of 44 years. In
the cholecystitis group, nine were male, eight female.
The age ranged from 25 to 79 years, with a mean of
55 years. After formation of a clot, sera were collected
and centrifuged at 1,000 rpm for 20 min. The super-
natant was carefully aspirated and stored at 80C
until analysis. The study protocol was approved by
Guangxi Medical University Ethics Committee. Writ-
ten informed consent to use the samples for research
was obtained from the patients and clinicians.
Methods
Measurements of serum DcR3 concentrations
To measure DcR3 concentrations in sera, a human
DcR3 ELISA kit (Bender Med Systems, Vienna,
Austria) was used according to the manufacturer’s
protocol. Brieﬂy, 100 mL of each sample was incu-
bated in duplicate in microplates coated with anti-
DcR3 monoclonal antibody for 2 h. Following
incubation, biotin-conjugate anti-DcR3 monoclonal
antibody was added and incubated as a primary
antibody for 2 h. After the microplate had been
washed, streptavidin-horseradish peroxidase (HRP)
was added and incubated for 1 h. After washing off
any unbound streptavidin-HRP, tetramethylbenzi-
dine was added as a substrate, and the absorbance
was measured at 450 nm after 20 min in a microplate
reader (BioTek Instruments, Burlington, VT, USA).
The absorbance of each sample was plotted against a
standard curve produced by serial dilutions of recom-
binant human DcR3-Fc in duplicate. The concentra-
tions of DcR3 in sera were calculated by logarithmic
analysis. All samples with an absorbance of less than
zero according to the standard curve were discarded
from the ﬁnal analysis. A concentration higher than
122.22 pg/mL was set as the positive level according
to the DcR3 average level in the normal control group
in our study.
Immunohistochemistry
The procedure employed has previously been
described (14). Sections of gastric carcinoma tissue
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positive controls. The primary antibody was replaced
by phosphate buffer solution for negative controls.
The positive signal for DCR3 appeared as yellow-
brown in the cytoplasm of the cells using 3,3¢-diami-
nobenzidine. One or two of the most representative
sections from each case were chosen and stained
with a rabbit polyclonal antibody against DcR3
(DcR3<H-130>:sc-25464, 1:300 dilution) from Santa
Cruz Biotechnology, Inc., Heidelberg, Germany,
which is raised against amino acids 171–300 of
DcR3 of human origin. One hundred cells from ﬁve
representative areas from each case were counted.
Staining results were evaluated according to immuno-
detection of stain intensity and number of positive
cells by two pathologists (G.C. and D.L.), who dis-
cussed each case until they reached a consensus.
Staining intensity was up to the standard of the relative
staining intensity of most cells. The degree of staining
was subdivided as follows: the staining intensity could
range from 0 to 3 (0 = no staining; 1 = yellow or light
brown, weak staining; 2 = brown, strong staining; and
3 = dark brown, intense staining), and the positive cells
in the observed liver tissues ranged from 0 to 3 in
percentage (0, no staining; 1, <30%, often focal or ﬁne
granular; 2, 30%–70%, linear or cluster; and 3 >70%,
diffuse). Samples were scored by their summation:
0–1( - ) ;2 –3( + ) ;4( + + ) ;5 –6 (+++). Any staining
score ‡2 (+) was considered as positive expression.
Statistical analyses
All data from ELISA were expressed as mean ±
standard deviation (SD). For normally distributed
data, the two-tailed Student’s t test and the Mann–
Whitney test were used for comparisons between
the two groups with SPSS 17.0 software for
Windows (Munich, Germany). Correlations were
calculated by Pearson chi-square test. In all cases,
a P value of less than 0.05 was considered statistically
signiﬁcant.
Results
Comparison of serum DcR3 concentrations and
DcR3 expression in different diseases
The serum concentration of DcR3 in the HCC
patients was higher than in the cholecystitis patients
and in the healthy controls (P < 0.01). Likewise, in the
cirrhosis patients the DcR3 serum concentration was
higher than that in the healthy controls (P < 0.01,
Table I). Quite in contrast, DcR3 serum concentra-
tions were not elevated in cholecystitis patients.
Relationship between serum DcR3 level of HCC and
clinicopathological parameters
Serum concentrations of DcR3 in patients with
clinical TNM stage III and IV were higher than in
patients at stages I and II. Serum concentrations of
DcR3 in patients with para-cirrhosis, capsular inﬁl-
tration, and metastasis or recurrence of disease were
signiﬁcantly higher than in those without (P < 0.05,
Table II).
Correlation between the concentration of serum
DcR3 and expression of DcR3 protein in HCC tissues
Sixty-four tissues from the total 67 cases were studied
with immunohistochemistry to detect the expression
of DcR3 protein (Figure 1). There was a positive
correlation between the concentrations of DcR3 in
sera and protein expression in HCC tissues (r = 0.472,
P < 0.01). The rate of DcR3 protein expression in
HCC tissues was 61% (39/64), which was lower than
the corresponding rate of DcR3 serum-positive
(higher than 122.22 pg/mL) patients (77%, 49/64,
P < 0.05, Table III). Likewise, 35 cases among the
39 DcR3 protein expression-positive patients were all
detected to be DcR3 serum-positive. Fourteen of the
serum DcR3-positives were found to be DcR3 protein
expression-negative.
Table I. Serum concentrations of DcR3 in different diseases.
Diseases DcR3 serum level (pg/mL) DcR3 expression rate
P compared with
Cirrhosis Cholecystitis Healthy controls
HCC 197.07 ± 90.34 51/67 (76%) 0.094 0.002 0.005
Cirrhosis 179.81 ± 102.74 5/8 (62%) — 0.083 0.003
Cholecystitis 101.59 ± 24.51 3/17 (18%) —— 0.102
Healthy controls 96.69 ± 16.05 1/28 (4%) —— —
234 M. Yang et al.Overall diagnostic effectiveness of mutual detection of
AFP and DcR3
The sensitivities of single detection of AFP and
DcR3 were 82% and 76%, respectively (detailed
data not shown). The sensitivity of combined detec-
tion of AFP and DcR3 increased to 93% (detailed
data not shown).
Discussion
Human DcR3 is a soluble receptor that is mostly
expressed in many different classes of tumors.
DcR3 is short of the transmembrane domain of con-
ventional Tumor Necrosis Factor Receptors (TNFRs)
and is thus believed to be a secreted protein (16). In
the present study, we determined the serum
DcR3 concentrations in 67 HCC patients, and
51 cases were positive (76%), signiﬁcantly higher
than that of cholecystitis and of healthy controls.
The present data conﬁrmed the results of Wu et al.
(8). This conﬁrmation indicates that serum concen-
trations of DcR3 in HCC are much higher than in
non-tumor controls. Our results also showed that
serum DcR3 concentrations were elevated in cirrhosis
patients. This ﬁnding was consistent with that of
Wu et al. (8), who reported elevated serum concen-
trations of DcR3 in ﬁve cirrhosis cases. In our previ-
ous studies we also found over-expression of DcR3 in
cirrhotic tissues (14). Our results together with the
data of Wu et al. suggest that there may be a link
between DcR3 expression and formation of cirrhosis.
Moreover, in HCC patients, DcR3 serum concentra-
tions in the para-cirrhosis-positive group were higher
than in the para-cirrhosis-negative group. Forty-four
Table II. Relationship between serum DcR3 concentrations and clinicopathological parameters in hepatocellular carcinoma (HCC).
HCC clinicopathological parameters
Serum DcR3
level (pg/mL)
Serum DcR3
expression rate P
Age ‡50 207.90 ± 82.76 25/30 (83%) 0.212
<50 189.76 ± 95.44 26/37 (70%)
Gender male 206.18 ± 92.69 47/58 (81%) 0.048
female 138.35 ± 40.37 4/9 (44%)
HBV positive 221.34 ± 64.34 45/51 (88%) 0.296
negative 198.14 ± 45.13 6/16 (38%)
HCV positive 208.73 ± 45.63 8/10 (80%) 0.187
negative 178.63 ± 61.04 43/57 (75%)
Differentiation well and moderately 187.89 ± 88.45 41/53 (77%) 0.106
poorly 231.84 ± 92.13 10/14 (71%)
Clinical TNM stage I–II 160.76 ± 62.57 26/37 (70%) 0.014
III–IV 224.78 ± 98.85 25/30 (83%)
Para-cirrhosis yes 212.76 ± 92.60 37/44 (84%) 0.005
no 150.94 ± 66.11 14/23 (61%)
Tumor capsular inﬁltration no capsular or capsular inﬁltration 219.52 ± 95.59 32/37 (86%) 0.015
no capsular inﬁltration 167.66 ± 74.70 19/30 (63%)
Portal vein tumor embolus yes 198.26 ± 84.80 9/11 (82%) 0.944
no 196.56 ± 93.48 42/56 (75%)
Tumor nodes multi 207.34 ± 94.55 20/25 (80%) 0.477
single 190.96 ± 88.33 31/42 (74%)
Tumor size (cm) ‡5 207.05 ± 89.54 35/43 (81%) 0.304
<5 184.00 ± 91.26 16/24 (67%)
AFP (mg/L) ‡400 213.10 ± 90.42 23/28 (82%) 0.327
<400 185.56 ± 89.66 28/39 (72%)
Metastasis or recurrence yes 215.04 ± 93.63 34/40 (85%) 0.02
no 164.88 ± 75.66 17/27 (63%)
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(Table II). Among these 44 patients, there were
37 (84%) who were serum DcR3-positive. Albeit
entirely speculatively, it might well be that a part of
their serum DcR3 derived from the para-cirrhosis.
It is known that HCC can result from pre-
cancerous liver disease, for instance cirrhosis. How-
ever, the molecular mechanisms in such a process
remain unclear. The high serum concentrations of
DcR3 in the cirrhosis patients and in the para-
cirrhosis HCC patients in the present study prompted
us to formulate a hypothesis concerning the potential
role of DcR3 in hepatocarcinogenesis. However, fur-
ther studies have to be carried out to prove the
hypothesis and investigate the value and mechanism
of DcR3 in liver cirrhosis and tumorigenesis of HCC.
To our knowledge, this is the ﬁrst study investigat-
ing a possible relationship between serum concentra-
tions and clinicopathological parameters of patients
in HCC. Another interesting observation in the pre-
sent study was that the serum concentration of
DcR3 directly correlated with para-cirrhosis, capsular
inﬁltration, and metastasis or recurrence of disease
(P < 0.05), revealing an obvious relation between
DcR3 and HCC malignant characteristics. As a
rule, the capsular inﬁltration and metastasis reﬂect
tumor growth and tumor invasive capability.
To date, to our knowledge there has been no study
reporting the association between the serum DcR3
concentration and the protein DcR3 expression in
HCC tissues. To answer this question, we performed
immunohistochemistry in 64 among the 67 HCC
patients to measure DcR3 protein expression and
compared it with the corresponding serum DcR3
concentration. Our results showed that there was
a positive correlation between the serum DcR3
concentration and the protein DcR3 expression
in HCC. However, the serum DcR3-positive rate
(77%) was higher than the corresponding tissue
DcR3 protein expression rate (39%). This was due
to 14 cases of negative expression of DcR3 protein in
patients, who were all that serum-positive. The var-
iation between serum and tissue DcR3 levels might
result from a difference in the sensitivity of the detect-
ing assays (ELISA versus immunohistochemistry).
Thus, using ELISA to estimate serum DcR3 con-
centrations seems more advantageous in clinical
application.
Taken together, our study demonstrates that the
measurements of serum DcR3 concentrations might
become of value for clinical early diagnosis, prognosis
prediction, and curative effects in HCC.
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Figure 1. Expression of DcR3 protein in hepatocellular carcinoma tissues. DcR3 protein was detected by immunohistochemistry in
hepatocellular carcinoma (HCC) tissues. (A: DcR3 negative; B: positive+; C: ++; D: +++). The signal was localized within the cytoplasm
of tumor cells in HCC tissues (400).
Table III. Correlation between the level of serum DcR3 and the
expression of DcR3 protein in hepatocellular carcinoma (HCC)
tissues.
Expression of
DcR3 protein in HCC
tissues
Level of serum DcR3 (pg/mL) n - + ++ +++
Negative (0–122.22) 15 11 4 0 0
Low level (122.23–149.99) 16 6 5 4 1
Moderate level (150.00–299.99) 20 6 8 4 2
High level (‡300.00) 13 2 4 2 5
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